The Impact of Programmed Cell Death on the Formation of Tertiary Lymphoid Structures
Overview
Affiliations
Tertiary lymphoid structures are clusters of lymphoid tissue that develop post-natally at sites of chronic inflammation. They have been described in association with infection, autoimmune disorders, cancer, and allograft rejection. In their mature stage, TLS function as ectopic germinal centers, favoring the local production of autoantibodies and cytokines. TLS formation tends to parallel the severity of tissue injury and they are usually indicative of locally active immune responses. The presence of TLS in patients with solid tumors is usually associated with a better prognosis whereas their presence predicts increased maladaptive immunologic activity in patients with autoimmune disorders or allograft transplantation. Recent data highlight a correlation between active cell death and TLS formation and maturation. Our group recently identified apoptotic exosome-like vesicles, released by apoptotic cells, as novel inducers of TLS formation. Here, we review mechanisms of TLS formation and maturation with a specific focus on the emerging importance of tissue injury, programmed cell death and extracellular vesicles in TLS biogenesis.
The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment.
Wang Y, Liu C, Pang J, Li Z, Zhang J, Dong L Small. 2025; 21(9):e2410503.
PMID: 39871756 PMC: 11878267. DOI: 10.1002/smll.202410503.
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.
Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z Signal Transduct Target Ther. 2024; 9(1):225.
PMID: 39198425 PMC: 11358547. DOI: 10.1038/s41392-024-01947-5.
Tumor Microenvironment Modulation by Cancer-Derived Extracellular Vesicles.
Ten A, Kumeiko V, Farniev V, Gao H, Shevtsov M Cells. 2024; 13(8.
PMID: 38667297 PMC: 11049026. DOI: 10.3390/cells13080682.
Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A Mol Cancer. 2024; 23(1):75.
PMID: 38582847 PMC: 10998345. DOI: 10.1186/s12943-024-01980-6.
Heterogeneity of tertiary lymphoid structures in cancer.
You X, Koop K, Weigert A Front Immunol. 2023; 14:1286850.
PMID: 38111571 PMC: 10725932. DOI: 10.3389/fimmu.2023.1286850.